SymBio Pharmaceuticals Limited
Completion of Patient Enrollment (FPI) in NIH-led Clinical Trial of IV BCV for Progressive Multifocal Leukoencephalopathy
Under a CRADA led by NIH/NINDS, the first patient enrollment for an IV BCV clinical trial targeting PML has been completed. The trial is conducted at the NIH Clinical Center in Bethesda, Maryland. No impact on the Full Year 2026 forecast. Continued development in the neurodegenerative disease area will be pursued.
Key Figures
- Clinical trial start: Enrollment of first patient completed
- Target disease: Progressive multifocal leukoencephalopathy (PML)
- Announcement date: 2026-06-09
AI要約
Progress on business and projects
SymBio Pharmaceuticals is advancing an IV BCV clinical trial for progressive multifocal leukoencephalopathy (PML) under the CRADA with NIH/NINDS, and has completed enrollment of the first patient. The trial, conducted at the NIH Clinical Center in Bethesda, is being led by Dr. Irene Cortese to evaluate efficacy and safety. PML is a severe brain disease caused by JC virus, with no established standard treatment.
Strategy and outlook
The company is pursuing BCV across three areas: (1) Phase III trial in infectious diseases, (2) clinical preparation in hematologic and solid tumors, and (3) development in neurodegenerative diseases, running in parallel. Through the CRADA targeting PML and multiple sclerosis with NIH collaboration, the aim is to accumulate clinical evidence and achieve global expansion of BCV.
SymBio Pharmaceuticals Limited
Company overview · Stock price · Financial data · All IR
